IKT
Inhibikase Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.50
−0.79%Aug 26, 2026, 00:00 UTC
Inhibikase Therapeutics dismissed its independent registered public accounting firm CohnReznick LLP and engaged Deloitte & Touche LLP as its new auditor, effective August 21, 2026.
Aug 11, 2026, 20:01 UTC
Inhibikase Therapeutics reported its financial results for the second quarter of 2026 on August 11, 2026.
Source:Jul 29, 2026, 00:00 UTC
Inhibikase Therapeutics exchanged 18,030,000 existing common shares for a pre-funded warrant to purchase 18,030,000 new shares, issued to RA Capital Healthcare Fund, L.P., with a $0.001 exercise price and a 9.99% beneficial ownership cap.
Jul 23, 2026, 12:00 UTC
The U.S. Food and Drug Administration granted Orphan Drug Designation to Inhibikase Therapeutics' IKT-001 for the treatment of Pulmonary Arterial Hypertension.
Source:Jul 14, 2026, 12:00 UTC
Inhibikase Therapeutics sold 25,000,000 shares of common stock to RA Capital Management through its ATM facility for gross proceeds of $50 million.
Source:Jun 29, 2026, 00:00 UTC
Inhibikase Therapeutics, Inc. elected Arvind Kush and Dennis Berman as Class III Directors of the Board of Directors, effective June 26, 2026.